Complete response for Pozen’s Trexima
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA has accepted Pozen's amended response to an "approvable" letter the firm received Aug. 1 for its migraine candidate Trexima (sumatriptan and naproxen sodium). The agency deemed the application complete, setting the clock for an April 15, 2008, user fee date, Pozen announces Nov. 1. The company submitted the NDA Aug. 8, 2005. GSK will market Trexima upon approval under a June 2003 agreement (1Pharmaceutical Approvals Monthly August 2005, p. 2). In Phase III studies, Trexima demonstrated statistical superiority for the primary endpoint of sustained pain-free response over the individual drugs sumatriptan and naproxen...
You may also be interested in...
Pozen Trexima NDA filing relieves MT 100 headache
Pozen's submission of an NDA for migraine treatment Trexima (sumatriptan/naproxen) Aug. 8, anticipated to receive a standard review, sets a user fee goal date of June 8, 2006. The submission follows a negative review of Pozen's MT 100 (naproxen/metoclopramide) combination migraine agent by FDA's Peripheral & Central Nervous System Drugs Advisory Committee Aug. 4. Pozen discontinued U.S. development of MT 100 the day after the meeting. GSK will market Trexima upon approval under a June 2003 agreement. In Phase III studies, Trexima demonstrated statistical superiority for the primary endpoint of sustained pain-free response over the individual drugs sumatriptan and naproxen. In addition, Phase III studies showed Trexima was statistically superior to its individual components in two-hour pain response endpoints, the company said...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.